Medexus Pharmaceuticals Inc.
MEDXF
$3.50
-$0.05-1.46%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -0.41% | -15.56% | -5.94% | -9.78% | -4.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.41% | -15.56% | -5.94% | -9.78% | -4.65% |
| Cost of Revenue | -9.68% | -28.33% | -19.32% | -23.54% | -11.58% |
| Gross Profit | 5.83% | -5.66% | 3.18% | -0.35% | 0.66% |
| SG&A Expenses | -13.02% | 2.23% | 23.00% | 17.56% | 17.43% |
| Depreciation & Amortization | 0.82% | 38.04% | 54.06% | 72.06% | 68.12% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.18% | -9.77% | 3.99% | 3.54% | 8.24% |
| Operating Income | 671.38% | -55.70% | -59.68% | -80.37% | -110.27% |
| Income Before Tax | -296.31% | -49.32% | 43.72% | -67.63% | -176.67% |
| Income Tax Expenses | -61.65% | 148.98% | 98.26% | 273.68% | -190.35% |
| Earnings from Continuing Operations | -383.73% | -89.09% | -386.36% | -73.63% | -172.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -383.73% | -89.09% | -386.36% | -73.63% | -172.57% |
| EBIT | 671.38% | -55.70% | -59.68% | -80.37% | -110.27% |
| EBITDA | 98.24% | -25.97% | -28.10% | -42.93% | -51.84% |
| EPS Basic | -342.78% | -91.58% | -317.78% | -80.00% | -159.94% |
| Normalized Basic EPS | 94.98% | -61.43% | -102.09% | -99.13% | -165.27% |
| EPS Diluted | -342.78% | -91.58% | -332.56% | -80.00% | -159.94% |
| Normalized Diluted EPS | 94.98% | -61.43% | -102.16% | -99.13% | -165.27% |
| Average Basic Shares Outstanding | 9.08% | 31.42% | 31.53% | 31.89% | 21.08% |
| Average Diluted Shares Outstanding | 9.08% | 31.42% | 27.12% | 31.89% | 21.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |